LeMaitre SVP sells 1,044 LMAT shares

LeMaitre Vascular senior vice president Trent G. Kamke reported multiple equity transactions.

Rhea-AI Filing Summary

LeMaitre Vascular senior vice president Trent G. Kamke reported multiple equity transactions. On February 27, 2026, he completed an open-market sale of 1,044 shares of common stock at $110.29 per share, after which he directly held 6,677 common shares.

On February 26, 2026, he acquired 1,051 common shares at no cost from the settlement and partial vesting of a performance share unit award, plus 2 additional shares from related dividend equivalent rights. Also on that date, 93 shares were withheld to cover tax obligations tied to the PSU vesting.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 5 txns

Insider Kamke Trent G

Role Senior V. P., Operations

Sold 1,044 shs ($115K)

Approx. gross sale proceeds $115K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Sale	Common Stock	1,044	$110.29	$115K
Exercise	Dividend Equivalent Rights	2	$0.00	$0.00
Grant/Award	Common Stock	1,051	$0.00	$0.00
Exercise	Common Stock	2	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	93	$113.69	$11K

Holdings After Transaction: Dividend Equivalent Rights — 6.6 contracts (Direct); Common Stock — 6,677 shares (Direct)

Footnotes (4)

1. F1. These shares represent LMAT common stock acquired on February 26, 2026, upon settlement of a Performance Share Unit (PSU) award granted on December 6, 2024. The PSU award vested 25% upon determination of satisfaction of the performance condition (on 2/26/2026), and the balance vests in equal annual installments on the grant date anniversary over the next three years.
2. F2. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.
3. F3. These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of PSUs awarded to the reporting person on December 6, 2024. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.
4. F4. These dividend equivalent rights were released in connection with the vesting of a PSU award granted on December 6, 2024. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did LMAT executive Trent G. Kamke report on this Form 4?

Trent G. Kamke reported an open-market sale of 1,044 LeMaitre Vascular common shares and several equity-related acquisitions and tax withholdings linked to a performance share unit award and dividend equivalent rights vesting on February 26 and 27, 2026.

How many LeMaitre Vascular (LMAT) shares did Trent G. Kamke sell and at what price?

He sold 1,044 shares of LeMaitre Vascular common stock in an open-market transaction at a price of $110.29 per share. This sale was reported as a standard open-market or private transaction under transaction code "S" on the Form 4.

What LMAT shares did Trent G. Kamke acquire from performance share units on February 26, 2026?

He acquired 1,051 shares of LeMaitre Vascular common stock at no cost upon settlement and partial vesting of a performance share unit award granted December 6, 2024. The award vested 25% after performance satisfaction, with remaining portions vesting annually over three years.

What are the dividend equivalent rights reported by Trent G. Kamke in LMAT stock?

Dividend equivalent rights are instruments economically equal to one share of common stock. Kamke reported their exercise and release connected to a performance share unit award, resulting in 2 additional LMAT common shares and 6.6 remaining dividend equivalent rights held directly after the February 26, 2026 transactions.

Why were 93 LMAT shares disposed of in a tax-withholding transaction by Trent G. Kamke?

The 93 LeMaitre Vascular shares were withheld by the company to satisfy tax withholding obligations from the vesting of performance share units granted on December 6, 2024. This disposition is treated as an exempt sale under Rule 16b-3(e) of the Securities Exchange Act.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 09:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kamke Trent G

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR , INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior V. P., Operations

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A		1,051(1)	A	$0	7,812	D
Common Stock	02/26/2026		M		2(2)	A	$0(2)	7,814	D
Common Stock	02/26/2026		F		93(3)	D	$113.69	7,721	D
Common Stock	02/27/2026		S		1,044	D	$110.29	6,677	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(4)	02/26/2026		M			2(4)	(4)	(4)	Common Stock	2	$0	6.6	D

Explanation of Responses:

1. These shares represent LMAT common stock acquired on February 26, 2026, upon settlement of a Performance Share Unit (PSU) award granted on December 6, 2024. The PSU award vested 25% upon determination of satisfaction of the performance condition (on 2/26/2026), and the balance vests in equal annual installments on the grant date anniversary over the next three years.

2. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.

3. These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of PSUs awarded to the reporting person on December 6, 2024. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.

4. These dividend equivalent rights were released in connection with the vesting of a PSU award granted on December 6, 2024. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Laurie A. Churchill, Attorney-in-fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.